NEW

Stock Screener with Intrinsic Value

TRY FOR FREE

Novo Nordisk A/S (NVO)

Last Price$78.7(5.3%)

Market Cap$350.5B

LTM Cash Flow from Operating Activities

$17.2B

YoY Growth

+12.7%

3Y CAGR

+22.5%

5Y CAGR

+18.3%

Stock quality & Intrinsic value

Start beating the S&P 500

Novo Nordisk A/S Cash Flow from Operating Activities

Annual

Quarterly

LTM

Crunching data... Almost there!

	Dec'04	Dec'05	Dec'06	Dec'07	Dec'08	Dec'09	Dec'10	Dec'11	Dec'12	Dec'13	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23
Cash Flow from Operating Activities	$1,278.8M	$1,646.7M	$1,300.7M	$1,834.5M	$2,538.1M	$2,872.7M	$3,496.6M	$3,982.7M	$3,826.4M	$4,610.4M	$5,644.1M	$5,696.6M	$7,177.2M	$6,246.2M	$7,064.2M	$7,005.6M	$7,945.8M	$8,741.2M	$11.2B	$15.8B

NVO

Key metrics and insights to make informed decisions.

View full analysis

Overvalued or undervalued?

Check the intrinsic value for NVO and see if it's the right time to invest.

Dive in

Novo Nordisk A/S (NVO) Cash Flow from Operating Activities comparison analysis

Crunching data... Almost there!

NVO key stats

USD

DKK

Millions

Billions

Annual

Quarterly

Trailing

Key stats

Income statement

Balance sheet

Cash Flow Statement

Valuation

Ratios

Per share

Per employee

Dividends & Yields

Crunching data... Almost there!

Discover more Stock Ideas

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%

S&P Outperformance 19.1%

Next 3M Predicted Return 20.3%

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%

S&P Outperformance 22.3%

Next 3M Predicted Return 26.8%

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.

3M Return 28.4%

S&P Outperformance 15.4%

Next 3M Predicted Return 16.9%

More ideas -->

Loved by
investors
worldwide

10K+

Investors use our platform

Top value investing hub with all necessary tools

1K+

Experienced investors in our community

4.9

Average rating across all rating platforms

Start for free ->

FAQ

1) What is Novo Nordisk A/S's Cash Flow from Operating Activities?

As of today, Novo Nordisk A/S's last 12-month Cash Flow from Operating Activities is $17.2B, based on the financial report for Sep 30, 2024 (Q3 2024).

2) What is Novo Nordisk A/S's Cash Flow from Operating Activities growth rate?

Over the last year, Novo Nordisk A/S's Cash Flow from Operating Activities growth was 12.7%. The average annual Cash Flow from Operating Activities growth rates for Novo Nordisk A/S have been 27.3% over the past three years, 18.3% over the past five years.

3) Is Novo Nordisk A/S's Cash Flow from Operating Activities growth rate Good?

Over the last year, Novo Nordisk A/S's Cash Flow from Operating Activities growth was 12.7%, which is higher than industry growth of (0.1%). It indicates that Novo Nordisk A/S's Cash Flow from Operating Activities growth is Good.

4) How does Novo Nordisk A/S's Cash Flow from Operating Activities growth rate compare to its peers?

Over the last year, Novo Nordisk A/S's Cash Flow from Operating Activities growth was 12.7%, which is higher than peer median growth of (90.0%). The list of peers includes REGN, RPRX, BNTX, UTHR, INCY, ALNY, SMMT, ARGX, BGNE, VRTX etc.